<p>The 13th Annual Utah Cardiac Recovery Symposium (U-CARS) brought together experts from around the globe to discuss advances in cardiac research, with an emphasis on the role of adrenergic receptors in heart disease and the use of β-blockers. Presentations highlighted new insights into β-adrenergic signaling, revealing how precise modulation of these pathways could enhance therapeutic outcomes and reduce adverse effects in heart failure (HF). Dr. Michael Bristow offered a comprehensive review of three decades of gene expression studies in the human heart. His talk highlighted how molecular profiles of β-adrenergic receptor subtypes evolve during disease progression and respond to pharmacological intervention. By outlining shifts in adrenergic receptors, along with related signaling pathways, Dr. Bristow emphasized opportunities for developing more targeted β -blocker strategies. These refined approaches along with guideline directed medical therapies could optimize patient outcomes by leveraging the intricate interplay between gene expression changes and receptor pharmacology. Next, studies were presented to understand how cells within the heart communicate with one another and with other organ systems to maintain cardiovascular homeostasis. Presenters described emerging data on signaling crosstalk between cardiomyocytes and non-myocyte cell populations, such as fibroblasts and immune cells that shape cardiac remodeling. These findings suggest that targeted manipulation of intercellular communication may protect the heart from stress-induced damage. The final series of molecular discussions explored the expanding view of HF as a multisystem syndrome that involves complex interactions between cardiovascular, renal, and metabolic processes. Research was focused on how aberrant molecular signals not only drive disease within the heart but also affect kidney function and systemic metabolism, further exacerbating HF progression. Speakers highlighted the clinical potential of integrated therapeutic strategies that use approaches to target the heart alongside renal and metabolic pathways. Synergistic approaches could better address the root causes of acute and chronic HF, slowing or reversing disease progression by restoring balanced interorgan communication.</p> Graphical Abstract <p>Central Summary Figure</p> <p>This central summary figure illustrates the major organ-to-organ pathways implicated in HF. Endocrine signaling (blue arrows) includes liver-derived FGF21 acting on the heart. Neural pathways (yellow arrows) represent sympathetic activation originating from the brain and influencing both cardiac and skeletal muscle responses. Metabolic interactions (red arrows) show bidirectional stress pathways between the heart, liver, and skeletal muscle. Additional heart-to-brain signaling via miRNA-enriched extracellular vesicles is shown at the top of the diagram. Together, these integrated pathways highlight the complexity of HF and underscore how dysfunction in one organ system may contribute to compensatory or maladaptive responses in others.</p> <p></p>